Where does Cyfuse Biomedical K.K. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cyfuse Biomedical K.K. ranks #31,343 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cyfuse Biomedical K.K. hold?

Cyfuse Biomedical K.K. holds 8 US utility patents granted between 2016 and 2025, spanning 7 technology areas.

What is Cyfuse Biomedical K.K.'s Innovation Score?

Cyfuse Biomedical K.K. has an Innovation Score of 29.5 out of 100 (31st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Cyfuse Biomedical K.K.'s patent grant rate increasing or decreasing?

Cyfuse Biomedical K.K.'s recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cyfuse Biomedical K.K.'s patents?

Cyfuse Biomedical K.K.'s patents average 9.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cyfuse Biomedical K.K. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cyfuse Biomedical K.K.

Q: What technology areas does Cyfuse Biomedical K.K. focus on?

Cyfuse Biomedical K.K.'s top technology area is C12M (Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters) with 7 patents, ranking #120 of 832 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12M (Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Ferme).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cyfuse ranks #31,343 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 7 technology areas.

#31,343
of 49,997 US assignees by volume: 31st percentile
by Innovation Score (29.5/100): 9.9
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R31343 · Foreign Corporation #31,343 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #31,343/49,997
PHOTO-FINISH Cake 0 emission AB
CPC-NARROW C12M · 7 areas
INNOV-THIN 29.5/100
CLAIMS-PAR 9.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cake 0 emission AB (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cyfuse’s 29.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (26%) Velocity 6.7 pts (23%) Breadth 9.4 pts (32%) Claim depth 5.9 pts (20%)

Qualcomm Incorporated · highest

85
Cyfuse Biomedical K K · this assignee

30
3D Lighting… · lowest

7

What this shows Cyfuse's Innovation Score is 29.5/100 (31st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cyfuse?

Each dot is one of Cyfuse’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cyfuse’s own 9.9 claims/patent is at or below the 15.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cyfuse vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cyfuse's grants concentrate

Cyfuse Biomedical K.K. is a focused PatentsView assignee: 7 CPC subclasses with 87.5% of grants classified under C12M (Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Ferme). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2018. By volume, Cyfuse sits between Cutting Edge Spine LLC and Calibre International, LLC.

Cyfuse's three-year grant acceleration

Cyfuse Biomedical K.K. shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cutting Edge Spine

8
CY Cergy Paris Un…

8
CY Vision

8
Cybertoka

8
Cake 0 emission AB

8
Calabazas Creek R…

8
Caliber

8
Calibre Internati…

8
Cyfuse Biomedical… ◀

8

What this shows Cyfuse holds 8 patents at rank #31,239, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cyfuse

By rank, the assignees closest to #31,239 in granted patent volume.

Leaders in C12M (Apparatus FOR Enzymology OR Microbiology)

Other assignees with the most granted patents in Cyfuse's primary technology class.

Cyfuse's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 31st percentile higher than 31% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Cyfuse Biomedical K.K. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	25.0%
2018	1	12.5%
2021	1	12.5%
2024	1	12.5%
2025partial year	3	37.5%

Which technologies does Cyfuse Biomedical K.K. patent most?

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 7

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

G06V - Image OR Video Recognition OR Understanding 1

B33Y - Additive Manufacturing, i.e. Manufacturing OF Three-dimensional [3-D] Objects BY Additive Deposition, Additive Agglomeration OR Additive Layering, e.g. BY 3-D Printing, Stereolithography OR Selective Laser Sintering 1

A61B - DIAGNOSIS; SURGERY; Identification 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cyfuse Biomedical K.K.'s patent record in context - here's where to go next.

Cyfuse Biomedical K.K.'s lead technology class is C12M (Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Ferme), 87.5% of its portfolio - see every assignee active in that class. Explore C12M
Ranked #31,343 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cyfuse Biomedical K.K. against Cutting Edge Spine LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.